PAX2
Paired box protein Pax-2
Also known as: PAX-2, PAX2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q02962
- Gene
- PAX2
- Ensembl
- ENSG00000075891
- Chromosome
- 10
- Canonical length
- 417 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm
- Secretome location
- Intracellular and membrane
OverviewNCBI Gene
PAX2 encodes paired box gene 2, one of many human homologues of the Drosophila melanogaster gene prd. The central feature of this transcription factor gene family is the conserved DNA-binding paired box domain. PAX2 is believed to be a target of transcriptional supression by the tumor suppressor gene WT1. Mutations within PAX2 have been shown to result in optic nerve colobomas and renal hypoplasia. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Dec 2014]
Canonical amino-acid sequenceUniProt
417 residues, UniProt reviewed canonical sequence.
>Q02962|PAX2
1 MDMHCKADPF SAMHPGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
61 SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVDKIA EYKRQNPTMF AWEIRDRLLA
121 EGICDNDTVP SVSSINRIIR TKVQQPFHPT PDGAGTGVTA PGHTIVPSTA SPPVSSASND
181 PVGSYSINGI LGIPRSNGEK RKRDEVEVYT DPAHIRGGGG LHLVWTLRDV SEGSVPNGDS
241 QSGVDSLRKH LRADTFTQQQ LEALDRVFER PSYPDVFQAS EHIKSEQGNE YSLPALTPGL
301 DEVKSSLSAS TNPELGSNVS GTQTYPVVTG RDMASTTLPG YPPHVPPTGQ GSYPTSTLAG
361 MVPGSEFSGN PYSHPQYTAY NEAWRFSNPA LLSSPYYYSA APRGSAPAAA AAAYDRHLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PAX2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.62
- Highest tissue expression
- 94 nTPM
Expression across tissuesHPA
Tissue
- kidney: 94 nTPM
- epididymis: 28 nTPM
- seminal vesicle: 11 nTPM
- fallopian tube: 7.5 nTPM
- parathyroid gland: 5.5 nTPM
- cervix: 3.8 nTPM
Single-cell type
- endometrial luminal cells: 544 nCPM
- renal collecting duct principal cells: 538 nCPM
- loop of henle epithelial cells: 341 nCPM
- epididymal principal cells: 336 nCPM
- renal connecting tubule cells: 327 nCPM
- proximal tubule cells: 297 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- medulla oblongata: 15 nTPM
- spinal cord: 13 nTPM
- pons: 7.4 nTPM
- cerebellum: 4.8 nTPM
- midbrain: 3.8 nTPM
- white matter: 2.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PAX2.
Disease | AllUniProt
Conditions PAX2 is implicated in, by any mechanism.
- Papillorenal syndrome (PAPRS) MIM:120330
- Focal segmental glomerulosclerosis 7 (FSGS7) MIM:616002
Disease | GeneticClinVar
144 pathogenic / likely-pathogenic of 635 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Renal coloboma syndrome
- Focal segmental glomerulosclerosis 7
- PAX2-Related Disorder
- Congenital anomalies of kidney and urinary tract 1
- Focal segmental glomerulosclerosis
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.43
- gnomAD pLI
- 0.67
- gnomAD missense Z
- 1.49
- DepMap mean gene effect
- -0.1
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- axonogenesis
- brain morphogenesis
- branching involved in ureteric bud morphogenesis
- camera-type eye development
- cell fate determination
- cellular response to glucose stimulus
- cellular response to retinoic acid
- cochlea development
- cochlea morphogenesis
- glial cell differentiation
- inner ear morphogenesis
- mesenchymal to epithelial transition
- mesenchymal to epithelial transition involved in metanephros morphogenesis
- mesodermal cell fate specification
- mesonephros development
- metanephric collecting duct development
- metanephric distal convoluted tubule development
- metanephric epithelium development
- metanephric mesenchymal cell differentiation
- metanephric mesenchyme development
- metanephric nephron tubule formation
- negative regulation of apoptotic process
- negative regulation of apoptotic process involved in metanephric collecting duct development
- negative regulation of apoptotic process involved in metanephric nephron tubule development
- negative regulation of DNA-templated transcription
- negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis
- negative regulation of mesenchymal cell apoptotic process involved in metanephros development
- negative regulation of programmed cell death
- negative regulation of reactive oxygen species metabolic process
- nephric duct formation
- nervous system development
- neural tube closure
- optic cup morphogenesis involved in camera-type eye development
- optic nerve development
- optic nerve morphogenesis
- optic nerve structural organization
- positive regulation of DNA-templated transcription
- positive regulation of epithelial cell proliferation
- positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis
- positive regulation of metanephric DCT cell differentiation
- positive regulation of metanephric glomerulus development
- positive regulation of transcription by RNA polymerase II
- pronephric field specification
- pronephros development
- regulation of metanephric nephron tubule epithelial cell differentiation
- regulation of metanephros size
- regulation of transcription by RNA polymerase II
- retinal pigment epithelium development
- sensory organ development
- stem cell differentiation
- ureter development
- ureter maturation
- urogenital system development
- vestibulocochlear nerve formation
- visual perception
- optic chiasma development
- positive regulation of optic nerve formation
Molecular functions
- cis-regulatory region sequence-specific DNA binding
- DNA binding
- DNA-binding transcription factor activity
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription cis-regulatory region binding
- transcription factor binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PAX2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PAX2 as an antibody target. Whether an autoantibody or antibody against PAX2 could matter depends on whether native PAX2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PAX2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PAX2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...